AB0663 PULMONARY INVOLVEMENT IN PATIENTS WITH SEROPOSITIVE AND ACPA POSITIVE RHEUMATOID ARTHRITIS (RA-ILD) – NOVEL SCREENING PROTOCOL FOR EARLY DETECTION OF PULMONARY INVOLVEMENT

类风湿性关节炎 医学 内科学 免疫学
作者
Martin Welcker,Frank Reichenberger,Carina Fischinger,Maxime Hoffmann,Nikolaus Kneidinger,Florian Popp,Werner von Wulffen
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:: 1618.1-1618
标识
DOI:10.1136/annrheumdis-2024-eular.902
摘要

Background:

Seropositive and ACPA positive Rheumatoid Arthritis (RA) is correlated with notable cardiovascular and pulmonary comorbidity1, 2.

Objectives:

Nevertheless, there is currently no established screening method for early detection of pulmonary involvement, particularly interstitial lung disease (ILD) in patients with seropositive and ACPA positive Rheumatoid Arthritis.

Methods:

In the context of this study we included in a first step an amount of 50 consecutive patients with a confirmed diagnosis of seropositive and ACPA positive Rheumatoid Arthritis without symptoms for or known cardiopulmonary disease. To screen for pulmonary, pleural or vascular manifestation of the disease we applied a noninvasive radiation-free method by means of pulmonary function tests (PFT), cardiopulmonary exercise test (CPET), echocardiography and pleuro-pulmonary transthoracic ultrasound (LUS).

Results:

For this analysis the data from 43 patients (mean age 58.5 years, 81.4% female, 93.02% non-smokers) were available, while we are still in the process of collecting data as part of the study's second step. With an average disease duration of 10.1 years and with a mean remission of DAS28 ESR 2.3, DAS28 CRP 2.2 or low disease activity (CDAI 6.2, SDAI 6.6), respectively, depending on the used disease activity score, 34.88 % showed an erosive course. In 3 patients we demonstrated a reduced forced vital capacity (FVC ≤80%) on PFT (6.98%), a reduced CO-diffusion capacity (DLCOc-SB ≤80%) in 14 patients (32.56%). Noticeable changes in LUS were detected in 39% of patients, 23% with a pattern compatible with ILD. ILD was suspected in 13% showing indications on LUS along with additional changes in PFT. Numerous other RA- and ILD-associated parameters were collected in the present study (Tables 1 and 2). Other findings included pleural consolidation suspicious for malignancy and pleural effusion on ultrasound, severe aortic stenosis in bicuspid aortic valve, severe impaired diffusion capacity due to lung emphysema and obstructive lung disease on pulmonary function tests. None of the patients showed signs of pulmonary vascular involvement or cardiac ischaemia on echocardiography or CPET.

Conclusion:

In conclusion screening of RA-patients for pulmonary involvement may reveal a considerable number of asymptomatic patients with signs consistent with pulmonary manifestation of rheumatoid arthritis, along with a variety of other cardiopulmonary comorbidities. For deeper validation of the presented results we continue to collect data in a second step of this study including additional 150 patients.

REFERENCES:

[1] Drosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Annals of the Rheumatic Diseases 2022; 81: 768 – 779. [2] Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev 2021; 30: 210011 [DOI: 10.1183/16000617.0011-2021]. Table 1. (descriptive characteristics, total sample, n = 43) Table 2.

Acknowledgements:

Acknowledgement text on presentation: This is an independent, investigator-initiated study supported by Boehringer Ingelheim, Germany. Boehringer Ingelheim has no role in the design, analysis or interpretation of the results in this study; Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to Boehringer Ingelheim substances, as well as intellectual property considerations.

Disclosure of Interests:

Martin Welcker Abbvie, Alexion, Aescu, Amgen, Biogen, BMS, Boehringer, Celltrion, Fresenius, Galapagos, Gilead, GSK, Hexal, Janssen, Medac, MSD, Mundipharma, Mylan, Novartis, Pfizer, Riemser, Roche, Sanofi-Aventis, SOBI, UCB, Abbvie, Alexion, Aescu, Amgen, Biogen, BMS, Boehringer, Celltrion, Fresenius, Galapagos, Gilead, GSK, Hexal, Janssen, Medac, MSD, Mundipharma, Mylan, Novartis, Pfizer, Riemser, Roche, Sanofi-Aventis, SOBI, UCB, Boehringer Ingelheim, Frank Reichenberger Boehringer Ingelheim, GSK, Roche, Boehringer Ingelheim, GSK, Roche, Boehringer Ingelheim, Carina Fischinger: None declared, Martin Hoffmann: None declared, Nikolaus Kneidinger: None declared, Florian Popp Boehringer Ingelheim, Werner von Wulffen Boehringer Ingelheim.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
落卿然完成签到,获得积分20
刚刚
崔诗云发布了新的文献求助10
刚刚
刚刚
赘婿应助醉熏的笑萍采纳,获得10
刚刚
啤酒完成签到,获得积分10
1秒前
天侠客完成签到,获得积分10
2秒前
温柔灵波完成签到 ,获得积分10
2秒前
lalala发布了新的文献求助10
2秒前
sciscisci发布了新的文献求助10
2秒前
猪猪hero发布了新的文献求助10
3秒前
unique发布了新的文献求助10
3秒前
量子星尘发布了新的文献求助10
4秒前
落卿然发布了新的文献求助10
4秒前
齐羽发布了新的文献求助10
5秒前
6秒前
乐乐应助旺旺小小酥采纳,获得50
7秒前
7秒前
活力友容发布了新的文献求助10
8秒前
9秒前
酱酱完成签到 ,获得积分10
9秒前
超级瑶瑶完成签到,获得积分20
9秒前
10秒前
10秒前
wjx发布了新的文献求助10
10秒前
Hello应助Stone采纳,获得10
11秒前
科研通AI5应助细腻涵菱采纳,获得10
11秒前
求求科研完成签到,获得积分10
12秒前
木子完成签到,获得积分10
12秒前
打打应助unique采纳,获得10
12秒前
Owen应助wonderingria采纳,获得10
12秒前
12秒前
12秒前
13秒前
飞快的惜灵完成签到,获得积分10
13秒前
小蘑菇应助齐羽采纳,获得10
13秒前
浮云发布了新的文献求助10
13秒前
今后应助股价采纳,获得10
13秒前
小耿完成签到 ,获得积分10
14秒前
qaa2274278941发布了新的文献求助10
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974463
求助须知:如何正确求助?哪些是违规求助? 3518823
关于积分的说明 11196212
捐赠科研通 3255008
什么是DOI,文献DOI怎么找? 1797655
邀请新用户注册赠送积分活动 877052
科研通“疑难数据库(出版商)”最低求助积分说明 806130